Publications en collaboration avec des chercheurs de Universidad Autónoma de Madrid (20)

2024

  1. Epidemiology and Risk Factors of Mycotic Aneurysm in Patients With Infective Endocarditis and the Impact of its Rupture in Outcomes. Analysis of a National Prospective Cohort

    Open Forum Infectious Diseases, Vol. 11, Núm. 3

  2. Torque teno virus: a potential marker of immune reconstitution in youths with vertically acquired HIV

    Scientific Reports, Vol. 14, Núm. 1

2023

  1. Treatment and prevention of monkeypox

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 41, Núm. 10, pp. 629-634

2021

  1. Prognostic models for mortality after cardiac surgery in patients with infective endocarditis: a systematic review and aggregation of prediction models

    Clinical Microbiology and Infection, Vol. 27, Núm. 10, pp. 1422-1430

2018

  1. Factors leading to the loss of natural elite control of HIV-1 infection

    Journal of Virology, Vol. 92, Núm. 5

  2. Mitochondrial haplogroup H is related to CD4+ T cell recovery in HIV infected patients starting combination antiretroviral therapy

    Journal of Translational Medicine, Vol. 16, Núm. 1

2016

  1. Clinical characteristics, treatment and outcomes of MRSA bacteraemia in the elderly

    Journal of Infection, Vol. 72, Núm. 3, pp. 309-316

  2. MicroRNA profile in CD8+ T-lymphocytes from HIV-infected individuals: Relationship with antiviral immune response and disease progression

    PLoS ONE, Vol. 11, Núm. 5

2015

  1. Methicillin-resistant Staphylococcus aureus (MRSA) catheter-related bacteraemia in haemodialysis patients

    BMC Infectious Diseases, Vol. 15, Núm. 1

2014

  1. Effects of sustained viral response in patients with HIV and chronic hepatitis C and nonadvanced liver fibrosis

    Journal of Acquired Immune Deficiency Syndromes, Vol. 66, Núm. 3, pp. 280-287

2013

  1. Predictive factors for mortality in patients with methicillin-resistant Staphylococcus aureus bloodstream infection: Impact on outcome of host, microorganism and therapy

    Clinical Microbiology and Infection, Vol. 19, Núm. 11, pp. 1049-1057

2012

  1. Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy

    Retrovirology, Vol. 9

2009

  1. HIV-1 reverse transcriptase thumb subdomain polymorphisms associated with virological failure to nucleoside drug combinations

    Journal of Antimicrobial Chemotherapy, Vol. 64, Núm. 2, pp. 251-258

  2. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-Week analysis

    Journal of Acquired Immune Deficiency Syndromes, Vol. 51, Núm. 2, pp. 147-152

2008

  1. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV

    AIDS, Vol. 22, Núm. 2

2007

  1. Effectiveness and safety of simplification therapy with once-daily tenofovir, lamivudine, and efavirenz in HIV-1-infected patients with undetectable plasma viral load on HAART

    HIV Clinical Trials, Vol. 8, Núm. 5, pp. 328-336

2005

  1. Treatment-limiting toxicities associated with nucleoside analogue reverse transcriptase inhibitor therapy: A prospective, observational study

    Current Therapeutic Research - Clinical and Experimental, Vol. 66, Núm. 2, pp. 117-129

2000

  1. Evaluating changes in health status in HIV-infected patients: Medical Outcomes Study-HIV and Multidimensional Quality of Life-HIV quality of life questionnaires

    AIDS, Vol. 14, Núm. 10, pp. 1439-1447

  2. Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain

    AIDS, Vol. 14, Núm. 6, pp. 727-732

1999

  1. A randomized study comparing instruments for measuring health-related quality of life in HIV-infected patients

    AIDS, Vol. 13, Núm. 13, pp. 1727-1735